BioMarin Pharmaceutical I... (BMRN)

The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d...

Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these...

BioMarin Pharmaceutical Inc.'s primary endpoint was met in the phase 3 Pegasus study, which used Palynziq for the treatment of adolescent patients ages 12 - 17 with phenylketonuria. The company is set...

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.